Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to -$2.6 million.

  • Cytosorbents' Free Cash Flow rose 80.31% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.0 million, marking a year-over-year increase of 4672.59%. This contributed to the annual value of -$14.7 million for FY2024, which is 3370.89% up from last year.
  • As of Q3 2025, Cytosorbents' Free Cash Flow stood at -$2.6 million, which was up 80.31% from -$1.3 million recorded in Q2 2025.
  • Cytosorbents' Free Cash Flow's 5-year high stood at -$1.3 million during Q2 2025, with a 5-year trough of -$11.1 million in Q2 2022.
  • Over the past 5 years, Cytosorbents' median Free Cash Flow value was -$4.9 million (recorded in 2024), while the average stood at -$5.1 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 47582.86% in 2021, then soared by 7306.22% in 2025.
  • Quarter analysis of 5 years shows Cytosorbents' Free Cash Flow stood at -$7.0 million in 2021, then grew by 20.93% to -$5.6 million in 2022, then decreased by 17.09% to -$6.5 million in 2023, then skyrocketed by 62.94% to -$2.4 million in 2024, then decreased by 7.63% to -$2.6 million in 2025.
  • Its last three reported values are -$2.6 million in Q3 2025, -$1.3 million for Q2 2025, and -$3.7 million during Q1 2025.